Correlation Between Amicus Therapeutics and Adaptimmune Therapeutics

Can any of the company-specific risk be diversified away by investing in both Amicus Therapeutics and Adaptimmune Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amicus Therapeutics and Adaptimmune Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Amicus Therapeutics and Adaptimmune Therapeutics Plc, you can compare the effects of market volatilities on Amicus Therapeutics and Adaptimmune Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amicus Therapeutics with a short position of Adaptimmune Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amicus Therapeutics and Adaptimmune Therapeutics.

Diversification Opportunities for Amicus Therapeutics and Adaptimmune Therapeutics

0.64

Correlation Coefficient

Amicus Therapeutics  Adaptimmune Therapeutics

Poor diversification

The 3 months correlation between Amicus and Adaptimmune is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Amicus Therapeutics and Adaptimmune Therapeutics Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adaptimmune Therapeutics and Amicus Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amicus Therapeutics are associated (or correlated) with Adaptimmune Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adaptimmune Therapeutics has no effect on the direction of Amicus Therapeutics i.e., Amicus Therapeutics and Adaptimmune Therapeutics go up and down completely randomly.

Pair Corralation between Amicus Therapeutics and Adaptimmune Therapeutics

Given the investment horizon of 90 days Amicus Therapeutics is expected to generate 0.28 times more return on investment than Adaptimmune Therapeutics. However, Amicus Therapeutics is 3.57 times less risky than Adaptimmune Therapeutics. It trades about -0.08 of its potential returns per unit of risk. Adaptimmune Therapeutics Plc is currently generating about -0.16 per unit of risk. If you would invest  984.00  in Amicus Therapeutics on December 22, 2024 and sell it today you would lose (83.00) from holding Amicus Therapeutics or give up 8.43% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Amicus Therapeutics  vs.  Adaptimmune Therapeutics Plc

Amicus Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Amicus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Adaptimmune Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Amicus Therapeutics and Adaptimmune Therapeutics

The main advantage of trading using opposite Amicus Therapeutics and Adaptimmune Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amicus Therapeutics position performs unexpectedly, Adaptimmune Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will offset losses from the drop in Adaptimmune Therapeutics' long position.

The idea behind Amicus Therapeutics and Adaptimmune Therapeutics Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.